Adjuvant Nivolumab/Ipilimumab vs Nivolumab in Resected Stage IIIB–D or IV Melanoma
Source: The Asco Post, October 2022
As reported in the Journal of Clinical Oncology by Jeffrey S. Weber, MD, PhD, and colleagues, the phase III CheckMate 915 trial showed no improvement in recurrence-free survival with adjuvant nivolumab/ipilimumab vs nivolumab in patients with resected stage IIIB–D or IV melanoma.
Study Details
In the double-blind trial, 1,833 patients from sites in 19 countries were randomly assigned between April 2017 and June 2018 to receive nivolumab at 240 mg every 2 weeks plus ipilimumab at 1 mg/kg every 6 weeks (n = 916) or placebo plus nivolumab at 480 mg every 4 weeks (n = 917) for up to 1 year. The dual primary endpoints were recurrence-free survival among all randomly assigned patients and in the tumor PD-L1 expression level < 1% subgroup; the latter consisted of 349 patients in the combination group and 351 in the nivolumab group.
Recurrence-Free Survival
At a minimum follow-up of approximately 23.7 months (median = 28.0 months in combination group and 28.1 months in nivolumab group), median recurrence-free survival was not reached in either group among all randomly assigned patients. Rates at 24 months were 64.6% in the combination group vs 63.2% in the nivolumab group (hazard ratio [HR] = 0.92, 97.3% confidence interval [CI] = 0.77–1.09, P = .269).